Navigating Tepezza Prior Authorization for Orthopedics

While Tepezza (teprotumumab) is primarily indicated for Thyroid Eye Disease (TED) and typically managed by ophthalmology or endocrinology, orthopedic practices within integrated health systems may still encounter Tepezza prior authorization requests.

Revenue cycle directors and prior authorization coordinators in orthopedic settings face unique challenges, from high-volume imaging and surgical procedure PAs to the complexities of managing specialty drugs. When a high-cost biologic like Tepezza appears in an orthopedic workflow, often due to co-management or system-level routing, it introduces distinct administrative hurdles that demand efficient solutions.

Tepezza's Role Beyond Traditional Orthopedics

Tepezza is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor approved for Thyroid Eye Disease (TED). Its clinical pathway, including diagnostic criteria and lines of therapy, is typically guided by ophthalmology and endocrinology specialists. Orthopedic practices are unlikely to initiate Tepezza prescriptions; however, within large health systems, PAs for patients receiving orthopedic care may include drugs managed by other specialties, necessitating a robust system for correct routing and processing.

Essential Documentation for Tepezza Prior Authorization

Should an orthopedic practice encounter a Tepezza PA, understanding the general documentation requirements is critical for efficient processing. These typically align with high-cost biologics and include evidence of a confirmed TED diagnosis, clinical symptoms and disease activity scores (e.g., Clinical Activity Score), documentation of prior failed conservative therapies, and a comprehensive treatment plan from the prescribing specialist. Access to a patient's full EMR, often via SMART on FHIR integration, is crucial for gathering this information.

Orthopedic PA Landscape and Cross-Specialty Overlap

Orthopedic prior authorization workflows are already complex, focusing heavily on advanced imaging (MRI/CT), major joint replacement, spine surgery, and durable medical equipment (DME). The high PA volume per surgeon practice, pre-operative scheduling pressures, and multi-step PA cascades (e.g., imaging → surgery) described in the corpus are primary concerns. Encountering a drug PA like Tepezza, which falls outside the typical orthopedic scope, adds an additional layer of administrative burden and highlights the need for adaptable PA automation.

Common Tepezza PA Considerations (Even if Not Ortho-Initiated)

**Specialty-Specific Criteria:** Payers often have specific coverage policies for Tepezza, requiring documentation of TED severity and previous treatment attempts.
**Medical Necessity Justification:** Detailed clinical notes from the prescribing ophthalmologist or endocrinologist are essential to demonstrate medical necessity.
**Step Therapy Requirements:** Some plans may require documentation of failed prior therapies for TED before approving Tepezza.
**Benefit Verification:** Confirming the correct medical or pharmacy benefit for Tepezza is crucial, as it can vary by plan.
**Peer-to-Peer Review:** Complex cases or initial denials may escalate to peer-to-peer discussions, typically between the prescribing specialist and the payer's medical reviewer.

Klivira's Solution for Integrated PA Management in Orthopedics

Klivira's platform is designed to manage the high volume and complexity of orthopedic PAs, from AAOS-guideline-aware conservative-care logic to multi-step PA cascade orchestration for imaging and surgery. For drugs like Tepezza that may appear in an orthopedic practice's queue, Klivira's EMR integration and automated routing capabilities ensure that even PAs outside the primary specialty are accurately identified, routed to the correct department, and processed with the necessary documentation, minimizing administrative burden and reducing potential delays for patient care.

Optimizing Workflow for Non-Standard PAs

By leveraging Klivira, orthopedic practices can enhance their ability to manage diverse prior authorizations, including those for high-cost biologics like Tepezza. Our system connects with payer portals, utilizes X12 278 transactions, and integrates with EMRs to pull relevant patient data. This ensures that whether it's an MRI for spine surgery or a Tepezza PA that landed in the orthopedic queue, the necessary information is compiled, submitted, and tracked efficiently, supporting timely approval and reducing denial rates across all encountered PA types.

Frequently asked questions

Why would an orthopedic practice encounter a Tepezza prior authorization?

An orthopedic practice might encounter a Tepezza PA primarily through administrative routing within an integrated health system, or if they are co-managing a patient who is also being treated for Thyroid Eye Disease (TED) by an ophthalmologist or endocrinologist. Orthopedists do not typically prescribe Tepezza.

What documentation is generally required for Tepezza PA, even if not initiated by orthopedics?

Key documentation includes a confirmed diagnosis of Thyroid Eye Disease (TED), detailed clinical notes from the prescribing specialist, disease activity scores, evidence of prior failed therapies (if applicable), and a comprehensive treatment plan. Access to the patient's full medical record via EMR integration is crucial for gathering this information.

How does Klivira help manage PAs for drugs outside our primary orthopedic specialty?

Klivira's platform provides robust EMR integration and automated routing logic. This allows our system to identify the appropriate specialty for a specific drug PA, ensure it's directed to the correct team, and facilitate the collection of necessary documentation, even for complex biologics like Tepezza that fall outside typical orthopedic care pathways.

Are there any musculoskeletal considerations for patients on Tepezza that an orthopedist should be aware of?

While Tepezza's primary action is for Thyroid Eye Disease, patients with TED may experience systemic inflammation or musculoskeletal symptoms indirectly related to their condition. Orthopedists should always conduct a thorough patient assessment and coordinate care with other specialists, especially when managing patients on complex drug regimens.